Uc health’s peripheral arterial ledderhose disease radiotherapy disease clinical trials — california

Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was ledderhose disease radiotherapy to test the hypothesis that canakinumab treatment of patients with ledderhose disease radiotherapy myocardial infarction (MI) at least one month prior to study entry and elevated ledderhose disease radiotherapy hsCRP could prevent recurrent cardiovascular events. The purpose of the extension phase of the main study ledderhose disease radiotherapy is to collect additional long-term safety data on continued exposure to canakinumab in patients ledderhose disease radiotherapy who participated in the pivotal phase. Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab ledderhose disease radiotherapy treatment for 24 months comparted with placebo on the carotid ledderhose disease radiotherapy plaque burden measured by integrated vascular MRI in patients enrolled ledderhose disease radiotherapy in the CACZ885M2301 study (CANTOS). Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS ledderhose disease radiotherapy main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion ledderhose disease radiotherapy and insulin sensitivity.

The purpose of the study is to learn which treatment ledderhose disease radiotherapy option is better for patients who have multi-vessel coronary artery disease (blockages in more than one vessel supplying blood to the ledderhose disease radiotherapy heart muscle). The treatment options this study will compare are: (1) Hybrid Coronary Revascularization [HCR] (a combination of surgery and catheter procedures to open up ledderhose disease radiotherapy clogged heart arteries) and (2) Percutaneous Coronary Intervention [PCI] (catheter procedures alone to open up clogged heart arteries). There are no new or "experimental" procedures being tested in this study: both HCR and PCI are well-established procedures and are regularly performed in patients who have ledderhose disease radiotherapy coronary artery disease. But, the FDA has not approved the drug-eluting stents used in PCI for all types of coronary ledderhose disease radiotherapy artery disease. We have received an Investigational Device Exemption from the FDA ledderhose disease radiotherapy to use the drug-eluting stents in this trial in the same way that ledderhose disease radiotherapy they are used in clinical practice. The study being proposed here will use rigorous scientific methods ledderhose disease radiotherapy and should result in a very high level of certainty ledderhose disease radiotherapy about which procedure is best for patients with coronary artery ledderhose disease radiotherapy disease.

This is a longitudinal observational study of HIV-infected patients and HIV-negative control patients that is being conducted to learn more ledderhose disease radiotherapy about immunologic factors, inflammation, and cardiovascular risk in patients with HIV infection or in ledderhose disease radiotherapy patients with autoimmune disease. The investigators plan to obtain measurement of carotid artery intima ledderhose disease radiotherapy media thickness (IMT) using high resolution ultrasound as a noninvasive means for tracking ledderhose disease radiotherapy atherosclerotic progression. The investigators will also measure lipid and lipoprotein levels, inflammatory markers, markers of Cytomegalovirus (CMV) infection, thrombotic markers, atherogenic lipoproteins, and markers of immune function. Immunophenotyping will be performed on freshly collected blood and analyzed ledderhose disease radiotherapy by flow cytometry to identify activated T-cells, T-cell turnover, proportions of T-cells, and CMV function. HIV-infected patients will have CD4 count and HIV viral load ledderhose disease radiotherapy measured in addition. Patients will undergo detailed clinical history including HIV disease, specific HIV medications, comorbid conditions, and health related behaviors. Physical exam and measurements will be obtained to assess for ledderhose disease radiotherapy the presence of lipodystrophy. Patients will undergo study visits for ultrasound, blood draw, and interview at 4-12 month intervals for the next 3 years. Patients will also go assessment of endothelial function, endothelial progenitor cells, arterial stiffness as measured using pulse wave tonometry. To demonstrate the feasibility of a larger scale investigation of ledderhose disease radiotherapy cardiac arrhythmia in HIV positive and negative patients with cardiac ledderhose disease radiotherapy disease, the investigators will use 48-hour Holter monitor surveillance to monitor HIV-infected and uninfected patients with a history of myocardial infarction, systolic left ventricular dysfunction, and/or pulmonary artery hypertension for the presence of cardiac arrhythmia. The FDG PET scan (18F-fluorodeoxyglucose positron emission tomography-computed tomography) will be used to detect and quantify inflammation in the ledderhose disease radiotherapy body.

The purpose of the ISCHEMIA trial is to determine the ledderhose disease radiotherapy best management strategy for higher-risk patients with stable ischemic heart disease (SIHD). This is a multicenter randomized controlled trial with 5179 randomized ledderhose disease radiotherapy participants with moderate or severe ischemia on stress testing. A blinded coronary computed tomography angiogram (CCTA) was performed in most participants with eGFR ≥60 mL/min/1.73m2 to identify and exclude participants with either significant unprotected ledderhose disease radiotherapy left main disease (≥50% stenosis) or those without obstructive CAD (<50% stenosis in all major coronary arteries). Of 8720 participants enrolled, those that had insufficient ischemia, ineligible anatomy demonstrated on CCTA or another exclusion criterion, did not go on to randomization. Eligible participants were then assigned at random to a routine ledderhose disease radiotherapy invasive strategy (INV) with cardiac catheterization followed by revascularization plus optimal medical therapy ledderhose disease radiotherapy (OMT) or to a conservative strategy (CON) of OMT, with cardiac catheterization and revascularization reserved for those who fail ledderhose disease radiotherapy OMT. SPECIFIC AIMS A. Primary Aim The primary aim of the ISCHEMIA trial is ledderhose disease radiotherapy to determine whether an initial invasive strategy of cardiac catheterization ledderhose disease radiotherapy followed by optimal revascularization, if feasible, in addition to OMT, will reduce the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure in participants ledderhose disease radiotherapy with SIHD and moderate or severe ischemia over an average ledderhose disease radiotherapy follow-up of approximately 3.5 years compared with an initial conservative strategy of OMT ledderhose disease radiotherapy alone with catheterization reserved for failure of OMT. B. Secondary Aims Secondary aims are to determine whether an initial ledderhose disease radiotherapy invasive strategy compared to a conservative strategy will improve: 1) the composite of CV death or MI; 2) angina symptoms and quality of life, as assessed by the Seattle Angina Questionnaire Angina Frequency and ledderhose disease radiotherapy Quality of Life scales; 3) all-cause mortality; 4) net clinical benefit assessed by including stroke in the primary ledderhose disease radiotherapy and secondary composite endpoints; and 5) individual components of the composite endpoints. Condition: Coronary Disease Procedure: Coronary CT Angiogram Procedure: Cardiac catheterization Phase: Phase III Condition: Cardiovascular Diseases Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions Phase: Phase III Condition: Heart Diseases Procedure: Coronary Artery Bypass Surgery Phase: Phase III

In this pilot study, investigators, in partnership with Resource Centers for Minority Aging Research (RCMAR) mentorship team and the MyMeds program, will enroll patients from MyMeds with diabetes, atherosclerotic cardiovascular disease, or congestive heart failure with poor medication adherence (medication adherence percentage<80% for statin or antihypertensive therapy) who report having a least one loved one or friend ledderhose disease radiotherapy (e.g., spouse) whom they consider to be invested in their health, and with whom they would be willing to share focused ledderhose disease radiotherapy medical information about medication adherence in the form of text ledderhose disease radiotherapy messages. Participants will be randomized into either a private feedback arm ledderhose disease radiotherapy or social network arm. In the private feedback arm, participants will only receive private consultations from a pharmacist regarding ledderhose disease radiotherapy their medication adherence rates. In the social network arm, participants and their chosen loved one or friend will receive ledderhose disease radiotherapy bi-weekly feedback text messages regarding the participant’s medication adherence. Investigators will evaluate the effects of this social network intervention ledderhose disease radiotherapy on medication adherence and examine the program’s acceptability among study participants. This proposal is innovative because it leverages social networks—largely unused in medical care—for health improvement.

Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain ledderhose disease radiotherapy genetic liver enzyme abnormality (known as cytochrome P450 2C19 [CYP2C19] 2 or 3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary ledderhose disease radiotherapy stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether ledderhose disease radiotherapy or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver ledderhose disease radiotherapy enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as ledderhose disease radiotherapy an anti-platelet agent after PCI. The purpose of this study is to determine if genetic ledderhose disease radiotherapy testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do ledderhose disease radiotherapy not activate clopidogrel very well.